Gene-editing tech firm Inscripta has made the strategic acquisition of life sciences company Illumina Biosciences for an undisclosed sum. The deal aims to speed up the commercialisation of Inscripta's CRISPR-based gene-editing technology tools, and will see Illumina CEO Tom Rosso – a former Solana executive – become VP of operations.
Gene-editing tech firm Inscripta has made the strategic acquisition of life sciences company Solana Biosciences for an undisclosed sum. The deal aims to speed up the commercialisation of Inscripta's CRISPR-based gene-editing technology tools, and will see Solana CEO Tom Rosso – a former Illumina executive – become VP of operations.